TAK

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Dollar change -0.08
Percentage change -0.60	%

Index	-	P/E	41.57	EPS (ttm)	0.32	Insider Own	0.02%	Shs Outstand	3.14B	Perf Week	-0.45%
Market Cap	41.77B	Forward P/E	24.60	EPS next Y	0.54	Insider Trans	0.00%	Shs Float	3.14B	Perf Month	1.22%
Income	1.01B	PEG	2078.39	EPS next Q	0.10	Inst Own	5.30%	Short Float	0.20%	Perf Quarter	-7.70%
Sales	29.50B	P/S	1.42	EPS this Y	26.50%	Inst Trans	11.74%	Short Ratio	3.78	Perf Half Y	-3.62%
Book/sh	15.31	P/B	0.87	EPS next Y	44.96%	ROA	0.99%	Short Interest	6.28M	Perf Year	-19.09%
Cash/sh	0.96	P/C	13.81	EPS next 5Y	0.02%	ROE	2.11%	52W Range	12.77 - 16.51	Perf YTD	-6.73%
Dividend Est.	0.62 (4.68%)	P/FCF	13.01	EPS past 5Y	-12.87%	ROI	1.30%	52W High	-19.41%	Beta	0.59
Dividend TTM	0.32 (2.40%)	Quick Ratio	0.58	Sales past 5Y	11.56%	Gross Margin	50.45%	52W Low	4.23%	ATR (14)	0.20
Dividend Ex-Date	Sep 28, 2023	Current Ratio	1.11	EPS Y/Y TTM	-56.91%	Oper. Margin	8.65%	RSI (14)	47.94	Volatility	0.81% 1.05%
Employees	49095	Debt/Eq	0.67	Sales Y/Y TTM	-0.70%	Profit Margin	3.43%	Recom	2.07	Target Price	15.85
Option/Short	Yes / Yes	LT Debt/Eq	0.62	EPS Q/Q	-109.33%	Payout	176.43%	Rel Volume	0.71	Prev Close	13.39
Sales Surprise	11.22%	EPS Surprise	-339.29%	Sales Q/Q	-2.00%	Earnings	May 09 AMC	Avg Volume	1.66M	Price	13.31
SMA20	0.52%	SMA50	-2.91%	SMA200	-7.80%	Trades		Volume	1,187,352	Change	-0.60%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy	$20
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform	$21 → $24
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform	$19.50
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

May-16-24 10:11AM	Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment (MT Newswires)
08:02AM	Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection (PR Newswire)
04:51AM	Takedas dengue vaccine obtains WHO prequalification (Pharmaceutical Technology)
May-15-24 01:52PM	Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification (MT Newswires)
May-14-24 12:23PM	Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute (MT Newswires)
10:01AM	Loading…
10:01AM	Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute (MT Newswires)
08:00AM	Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting (Business Wire)
May-13-24 11:22AM	Takeda shells out $100m to license AC Immunes Phase II Alzheimers therapy (Pharmaceutical Technology)
08:02AM	Takeda nabs option to license Alzheimers immunotherapies from AC Immune (BioPharma Dive)
07:26AM	Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate (MT Newswires)
06:00AM	AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease (GlobeNewswire)
May-10-24 09:30AM	Catalyst's New CEO Has Big Ideas For The Small Biotech (Investor's Business Daily)
May-09-24 03:46PM	Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50% (Benzinga)
10:03AM	Takeda tackles $900m restructuring plan after generics hurt annual profits (Pharmaceutical Technology)
07:52AM	Takeda targets efficiency in restructuring, pipeline cuts (BioPharma Dive)
06:52AM	Loading…
06:52AM	TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023 (InvestorPlace)
04:23AM	Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued (MT Newswires)
02:56AM	Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss (The Wall Street Journal)
02:07AM	Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion (Business Wire)
May-08-24 07:51PM	Nikkei Up 0.2%, Led by Banks, Insurers (The Wall Street Journal)
May-07-24 09:04PM	Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations (GuruFocus.com)
May-06-24 02:06PM	How the Medical Industry Could Produce the Biggest AI Stock Winners (InvestorPlace)
Apr-29-24 09:35AM	Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround (Zacks)
Apr-26-24 10:06AM	European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer (MT Newswires)
09:35AM	Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround (Zacks)
08:30AM	Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer (Business Wire)
08:30AM	HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda (GlobeNewswire)
Apr-25-24 12:00PM	All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy (Zacks)
11:34AM	20 Fastest Growing Health Tech Companies in the World (Insider Monkey)
09:40AM	Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? (Zacks)
10:00AM	Loading…
Apr-23-24 10:00AM	Takeda Pharmaceutical: A Long-Term Cash Cow (GuruFocus.com)
07:00AM	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder (PR Newswire)
Apr-22-24 05:50AM	Pharmas form joint venture to jumpstart Japanese drug research (BioPharma Dive)
04:10AM	Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs (PR Newswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-18-24 07:00PM	U.S. FDA Approves Subcutaneous Administration of Takedas ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohns Disease (Business Wire)
Apr-08-24 08:00AM	Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food (Business Wire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-27-24 08:56AM	Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE (PR Newswire)
Mar-26-24 07:07PM	Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting (Business Wire)
08:00AM	Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Business Wire)
Mar-19-24 12:20PM	Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL (Business Wire)
06:30AM	CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders (GlobeNewswire)
Mar-14-24 02:15AM	Japans Stock Market Is Back, and It Isnt Too Late to Buy (Barrons.com)
Mar-13-24 08:00AM	Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia (Business Wire)
Mar-11-24 12:00PM	Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? (Zacks)
Mar-09-24 01:07PM	5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-26-24 11:30PM	Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas (Business Wire)
11:30PM	Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E. (PR Newswire)
07:00AM	Championing Rare Voices on Rare Disease Day (PR Newswire)
Feb-24-24 05:06AM	5 Best Japanese Stocks To Buy In 2024 (Insider Monkey)
Feb-23-24 05:43AM	20 Fastest Growing Biotech Companies in the US (Insider Monkey)
Feb-21-24 06:56AM	Q4 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-12-24 08:32AM	UPDATE 2-Takeda's treatment becomes first oral therapy for esophageal condition in US (Reuters)
08:10AM	US FDA approves Takeda's therapy for allergic inflammation in esophagus (Reuters)
08:00AM	FDA Approves Takedas EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) (Business Wire)
Feb-10-24 08:30AM	30 Most Valuable Drug Companies in 2024 (Insider Monkey)
Feb-09-24 07:08AM	Takeda speeds narcolepsy drug to late-stage testing (BioPharma Dive)
Feb-08-24 06:00PM	Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 (Business Wire)
Feb-01-24 06:35AM	Takeda pays $300M to license Protagonist drug for blood disorder (BioPharma Dive)
01:54AM	Takeda Announces Chief Financial Officer Succession (Business Wire)
01:47AM	Takeda Pharmaceuticals Third-Quarter Net Profit Dropped on Lower Margins (The Wall Street Journal)
01:02AM	Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products (Business Wire)
Jan-31-24 07:19PM	Nikkei Down 0.4%, Dragged by Auto, Machinery Stocks (The Wall Street Journal)
04:05PM	Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset (ACCESSWIRE)
Jan-29-24 11:10AM	Takedas GAMMAGARD LIQUID Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Business Wire)
02:00AM	Takedas HYQVIA Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Business Wire)
Jan-25-24 05:00PM	Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation (PR Newswire)
04:52PM	Cancer drugmaker ArriVent follows on CGs heels with $175M IPO (BioPharma Dive)
Jan-18-24 07:00AM	Takeda Named Global Top Employer for Seventh Consecutive Year (Business Wire)
Jan-16-24 08:00AM	U.S. FDA Approves Takedas HYQVIA as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Business Wire)
Dec-22-23 05:35AM	One Ultra-Cheap High-Yield Dividend Stock to Buy (Motley Fool)
Dec-21-23 04:00PM	Takeda Announces China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies (Business Wire)
Dec-20-23 07:01AM	Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema (PR Newswire)
Dec-19-23 11:41AM	13 Most Promising Healthcare Stocks According to Analysts (Insider Monkey)
Dec-15-23 08:16AM	Takeda Receives Positive CHMP Opinion for HYQVIA as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Business Wire)
Dec-12-23 03:04PM	30 Largest Pharmaceutical Companies in the World (Insider Monkey)
Dec-11-23 10:24AM	20 Developed Countries in Asia (Insider Monkey)
Dec-07-23 09:40AM	Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? (Zacks)
Dec-05-23 08:00AM	Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners (Business Wire)
Nov-27-23 08:00AM	Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases (Business Wire)
Nov-17-23 09:40AM	Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? (Zacks)
Nov-16-23 07:47PM	Nikkei Falls 0.2% as Consumer, Healthcare Stocks Weigh (The Wall Street Journal)
Nov-09-23 03:50PM	UPDATE 2-Takeda Pharma gets US FDA approval for rare blood disorder therapy (Reuters)
03:50PM	Takedas ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Business Wire)
03:06PM	US FDA approves Takeda's blood disorder therapy (Reuters)
08:38AM	WAVE Life Sciences Ltd (WVE) Reports Notable Shift to Profitability in Q3 2023 (GuruFocus.com)
07:00AM	Takeda secures FDA approval for colon cancer drug (BioPharma Dive)
Nov-08-23 05:54PM	Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer (Business Wire)
Nov-07-23 10:00AM	Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting (Business Wire)
Oct-27-23 01:10PM	Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2023 Earnings Call Transcript (Insider Monkey)
11:40AM	TAK vs. STVN: Which Stock Is the Better Value Option? (Zacks)
Oct-26-23 08:37PM	Nikkei Rises 0.3%, Led by Electronics, Tech Stocks (The Wall Street Journal) -7.72%
04:44AM	Takeda Pharmaceutical Books Second-Quarter Net Loss (The Wall Street Journal)
02:00AM	Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance (Business Wire)
Oct-19-23 10:32AM	10 Best Japanese Stocks To Invest in 2023 (Insider Monkey)
Oct-18-23 04:30PM	European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD (Business Wire)
Oct-17-23 07:30PM	Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire (Business Wire)
07:30PM	Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel (darvadstrocel) in Complex Crohns Perianal Fistulas (Business Wire)

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TAKEDA PHARMACEUTICAL CO LTD	10% Owner	Jan 24 '24	Sale	8.10	3,703,703	29,999,994	3,755,583	Jan 25 06:13 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Takeda Pharmaceutical Co ADR

Upgrade your FINVIZ experience